Progress on targets and therapeutic drugs for pancreatic cancer
10.16438/j.0513-4870.2022-0824
- VernacularTitle:胰腺癌药物靶点及治疗药物的研究进展
- Author:
Hong YANG
;
Wan LI
;
Sha LI
;
Li-wen REN
;
Yi-zhi ZHANG
;
Yi-hui YANG
;
Bin-bin GE
;
Xiang-jin ZHENG
;
Jin-yi LIU
;
Sen ZHANG
;
Guan-hua DU
;
Jin-hua WANG
- Publication Type:Research Article
- Keywords:
pancreatic cancer;
chemotherapy;
rug target;
targeted therapy;
immunotherapy
- From:
Acta Pharmaceutica Sinica
2023;57(1):9-20
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic cancer is a highly malignant tumor with a poor prognosis. It is very hard to treat pancreatic cancers for their high heterogeneity, complex tumor microenvironment, and drug resistance. Currently, gemcitabine plus nab-paclitaxel, capecitabine and FOLFIRINOX are standard chemotherapy for resectable or advanced metastatic pancreatic cancer. Considering the limited efficacy and toxic side effects of chemotherapy, targeted and immune drugs have gradually attracted attention and made some progress. In this article, we systematically reviewed the chemotherapeutic drugs, targets and related targeted drugs, and immunotherapy drugs for pancreatic cancer.
